Lee’s Pharmaceutical Holdings Limited 2025 Annual Report: Key Highlights and Insights for Investors

Robust Revenue Performance and Strategic Milestones

Lee’s Pharmaceutical Holdings Limited delivered a resilient performance in 2025, reporting a historic milestone with revenue surpassing HK\$1.4 billion, a year-on-year growth of 2.6%. This achievement is underpinned by an increasingly diversified product portfolio, now comprising over 25 commercialised products across Mainland China, Hong Kong, Macau, and Taiwan.

• Total Revenue (2025): HK\$1,435,980,000
• Gross Profit (2025): HK\$729,560,000 (down 3.2% YoY)
• Net Profit Attributable to Shareholders: HK\$91,938,000 (down 1.2% YoY)
• Basic Earnings Per Share: HK15.61 cents (compared to HK15.81 cents in 2024)

Dividend Policy and Shareholder Returns

Despite margin pressures and currency headwinds, the Board proposed a final dividend of HK2.3 cents per share, with a total dividend for the year maintained at HK4.5 cents per share. The dividend payout ratio stood at 28.8%, underscoring the Group’s commitment to rewarding shareholders even in a challenging environment. The final dividend is subject to approval at the forthcoming AGM and is scheduled for payment on 15 June 2026.

Operational Efficiency and Cost Control

Lee’s Pharmaceutical demonstrated disciplined cost management, most notably in selling and distribution expenses, which saw a significant reduction of 13.8% to HK\$333,980,000. The selling expense to revenue ratio improved to 23.3% from 27.7% the previous year. This efficiency gain was due to the non-recurrence of one-off launch and promotional costs incurred in FY2024.

• Selling & Distribution Expenses: HK\$333,980,000 (down from HK\$387,292,000)
• Administrative Expenses: HK\$222,981,000 (up 14.2%, attributed to U.S. operations expansion and asset acquisitions)
• Research & Development Expenses: HK\$110,957,000 (up 32% YoY)

Strategic Investments and International Expansion

The Group continued to strengthen its international footprint, particularly through U.S.-based operations and asset acquisitions, reflected in higher administrative and professional fees. The company’s R&D focus remains highly selective, concentrating on projects with strong commercial potential and marketability, while discontinuing those deemed unsuitable. Notably, HK\$16 million in non-recurring impairment charges were recognized, reflecting the prudent approach to portfolio management.

Financial Position and Liquidity

Lee’s Pharmaceutical ended 2025 with a net cash position of HK\$54,262,000, a significant improvement from HK\$2,980,000 the previous year. The current ratio improved slightly to 1.03. The Group’s conservative treasury policies and close monitoring of credit and liquidity risks reinforce its financial strength, suggesting adequate resources to meet future operational and development needs.

• Net Cash Position (2025): HK\$54,262,000
• Current Ratio: 1.03
• Gearing Ratio: Nil

Diversified Product Portfolio and Market Access

A key highlight is the Group’s successful diversification away from reliance on a single blockbuster product. Multiple products—including Ferplex, Yallaferon, Treprostinil Injection, and Nadroparin Calcium Injection—each generated over HK\$200 million in annual revenue, with Bredinin and Trittico contributing more than HK\$100 million each. Additionally, 10 products are now listed on China’s National Reimbursement Drug List (NRDL), enhancing market access and patient affordability.

Key Risks and Governance

The Board acknowledges ongoing risks including:

• Policy-driven pricing pressures (notably from China’s VBP program and national reimbursement reforms)
• Rising competition and rapid market changes
• Foreign exchange volatility (notably a shift from FX gain in 2024 to FX loss in 2025)
• Operational risks related to expansion and manufacturing

The Group’s internal controls, risk management systems, and compliance policies are reviewed regularly and deemed effective by the Board.

Share Option Schemes and Management Incentives

The Company operates both the 2012 and 2022 Share Option Schemes, with a focus on incentivizing key employees, directors, and contributors. As at 31 December 2025, 21,679,000 options remained outstanding under the 2012 scheme and 4,778,000 under the 2022 scheme. The fair value of share options granted in 2025 was estimated at HK\$897,000, and the total share-based payment expense for the year was HK\$515,000.

Related Party Transactions and Connected Transactions

There were no material related party or connected transactions requiring shareholder approval or disclosure under the Listing Rules, save for a continuing guarantee provision to an associate (PPI) which has not exceeded its disclosed cap and has been confirmed as fair, reasonable, and in the interests of shareholders by both independent directors and the auditor.

Price-Sensitive and Investor-Relevant Matters

• Stable Profitability and Unchanged Dividend: The Group maintained profitability and dividend payout despite industry headwinds, reflecting operational resilience.
• Successful Portfolio Diversification: Reduced reliance on single products mitigates risk and supports long-term growth prospects.
• Impairment Charges and R&D Discipline: Non-recurring impairment signals a prudent portfolio approach but may impact short-term earnings.
• Expansion into the U.S. Market: Increased administrative costs and investments signal a strategic push for international growth, with potential for future revenue streams.
• Improved Liquidity and Financial Strength: Significant improvement in net cash position enhances financial flexibility for future growth and M&A activity.
• Foreign Exchange Losses: A shift from FX gains to losses contributed to a softer bottom line and may remain a risk factor depending on future currency movements.

Conclusion

Lee’s Pharmaceutical Holdings Limited’s 2025 performance shows resilience and adaptability amid a challenging market landscape. While profit and margin pressures persist, the company’s strategic focus on product diversification, international expansion, prudent R&D investment, and cost discipline positions it for sustained growth. The maintenance of dividend levels and improved liquidity are likely to be well received by investors, although ongoing policy risks and foreign exchange volatility remain key factors to monitor.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult their financial advisors before making investment decisions. All financial data are based on the company’s 2025 annual report.

View LEE’S PHARM Historical chart here